Mateon Therapeutics Inc  

(Public, OTCMKTS:MATN)   Watch this stock  
Find more results for NASDAQ:OXGN
0.389
-0.020 (-4.79%)
Jan 20 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.38 - 0.42
52 week 0.27 - 1.02
Open 0.41
Vol / Avg. 18,735.00/175,639.00
Mkt cap 10.33M
P/E     -
Div/yield     -
EPS -0.53
Shares 26.54M
Beta 1.52
Inst. own 19%
Mar 27, 2017
Q4 2016 Mateon Therapeutics Inc Earnings Release (Estimated) Add to calendar
Nov 14, 2016
Q3 2016 Mateon Therapeutics Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.88% -47.18%
Return on average equity -75.05% -50.24%
Employees 13 -
CDP Score - -

Address

701 Gateway Blvd Ste 210
SOUTH SAN FRANCISCO, CA 94080-7041
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

Description

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Officers and directors

William D. Schwieterman M.D. Chairman of the Board, President, Chief Executive Officer
Age: 58
Matthew M. Loar CPA Chief Financial Officer, Principal Accounting Officer
Age: 51
David Chaplin Ph.D. Chief Scientific Officer, Director
Age: 59
Simon C. Pedder Ph.D. Director
Age: 55
Donald R. Reynolds Independent Director
Age: 54
Bobby W. Sandage Jr., Ph.D. Independent Director
Age: 63